Latest Breaking News On - Prnewswire vesper bio - Page 1 : vimarsana.com

Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia

COPENHAGEN, Denmark, May 30, 2024 /PRNewswire/ Vesper Bio ApS ("Vesper" or "the Company"), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion

Prnewswire vesper bioVesper bioLundbeckfonden biocapitalPaul littleBio apsChief medical officerChief executive officerIhr portfolio

Vesper Bio awarded grant by The Michael J Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson s disease

/PRNewswire/ Vesper Bio ApS ("Vesper" or "the Company"), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the.

Anders nykjAnders nykjaerPrnewswire vesper bioVesper bioParkinson disease therapeutics pipeline program preTranslational researchLouise klem senior research scientistMichaelj fox foundation for parkinson researchLouise klemSenior research scientistDisease therapeutics pipeline programPhase ib proof of conceptPhd chief scientific officerTome garciaAssociate directorFrontotemporal dementia

Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)

Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Prnewswire vesper bioVesper bioAnders nykjaerLundbeckfonden biocapitalPaul littleLundbeck foundationAarhus universityResearch at aarhus universityFrontotemporal dementiaChief executive officerPhd chief scientific officerFronto temporal dementiaPhase ib proof of conceptProfessor anders nykjaerBringing discoveriesFerrosan medical devices